Key result
Eribulin yields 8-month disease control without adverse effects in a heavily pretreated dedifferentiated liposarcoma case.
Why the study?
Liposarcoma has limited therapeutic options due to its low incidence, and eribulin was recently approved for advanced liposarcoma after progression on at least two chemotherapy lines.
Case Report (n=1)
Eribulin demonstrated efficacy and safety in a heavily pretreated patient with dedifferentiated liposarcoma, highlighting the importance of accurate molecular profiling.
May warrant consideration in refractory cases; single case report leaves open need for prospective validation.
Due to its low incidence, liposarcoma displays a limited number of therapeutic options. However, eribulin recently received approval for the treatment of advanced liposarcoma patients, progressing to at least two chemotherapy lines. We report herein the case of a man initially diagnosed with a leyomiosarcoma, subsequently reclassified as a dedifferentiated liposarcoma, who received eribulin after he failed several therapy lines. Eribulin provided our patient an 8-month disease control and a substantial clinical benefit with no relevant adverse effects, showing a good efficacy and safety profile despite its delayed employ. Additionally, this case strengthens the pivotal importance of molecular profiling in the management of soft tissue sarcomas.
No takes yet. Share an insight, caveat, or question.
Martorana et al. (2020) conducted a case report in Dedifferentiated liposarcoma (n=1). Eribulin was evaluated on Disease control and clinical benefit. Eribulin provided an 8-month disease control and substantial clinical benefit with no relevant adverse effects in a heavily pretreated patient with dedifferentiated liposarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: